MedDataX Logo

Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis

NCT ID: NCT00173706

Last Updated: 2006-03-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study designed to test the hypothesis that treatment with L-carnitine will improve the quality of life and some specific symptoms and signs in patients with renal failure submitted to hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

L-Carnitine is a naturally occurring compound that facilitates the transport of fatty acids into mitochondria for beta-oxidation. A lack of carnitine in hemodialysis patients is caused by insufficient carnitine synthesis and particularly by the loss through dialytic membranes, leading in some patients to carnitine depletion with a relative increase of esterified forms. Many studies have shown that L-carnitine supplementation leads to improvements in several complications seen in uremic patients, including cardiac complications, impaired exercise and functional capacities, muscle symptoms, increased symptomatic intradialytic hypotension, and erythropoietin-resistant anemia, normalizing the reduced carnitine palmitoyl transferase activity in red cells.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Complications Signs and Symptoms Muscle Weakness Anemia Hypotension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-Carnitine Injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with the following criteria will be eligible for participation in this study:

1. Male or female adults over 18 years of age
2. On hemodialysis for at least one year
3. Interdialysis weight gain \< 5%
4. Bicarbonate dialysis 3 times per week
5. Modality of dialysis unchanged for 3 months prior to entry into the study (concerning dialysis-time and mode: bicarbonate, acetate dialysis)
6. Have one of the following symptoms and signs that have not responded to diet or pharmacological intervention:

1. persistent weakness affecting daily life
2. malnutrition
3. anemia (hemoglobin \[Hb\] \< 12 g/dl; hematocrit \[Hct\] \< 30%)
4. experiencing intradialytic complications (cramping, muscular pain, hypotension, hypertension, head-ache)
7. On regular treatment with vitamin B12 and folates
8. Normal iron status (ferritin \> 100 ng/ml; transferrin saturation \[TSAT\] \> 20%)
9. Informed consent obtained
10. Patients with diabetes mellitus are allowed to enter the study if they have stable glycaemic control on diet or pharmacological treatment.

Exclusion Criteria

Patients displaying one or more of the following criteria will not be eligible for participation in this study:

1. Severe uncontrolled hypertension (systolic \> 170; diastolic \> 115) outside of dialysis
2. Some patients have echocardiogram (ECHO) defined chronic heart failure. Patients with New York Heart Association (NYHA) class II and class III can be admitted. Patients with class IV must be excluded. Some patients have angina. Patients with stable effort angina well controlled by treatment can be recruited. Absolute exclusion for angina at rest.
3. Major hepatic diseases - chronic active (aggressive) hepatitis or cirrhosis
4. Systemic haematological diseases and tumours
5. Uncontrollable diabetes
6. History of drug and alcohol abuse
7. Positive screening for HIV antibodies
8. Life expectancy of less than one year
9. Uncontrolled hyperparathyroidism (patients with stable bone status can be recruited)
10. Use of immunodepressants during the preceding 4 weeks
11. Changes in corticoid therapy in the preceding 4 weeks
12. Use of experimental drugs during the preceding 4 months
13. Use of L-carnitine during the preceding 4 months
14. Informed consent not obtained
15. Pregnancy
16. Patients already included in other clinical trials.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kwan-Dun Wu, Ph.D

Role: STUDY_DIRECTOR

National Taiwan University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, Taipei, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kwan-Dun Wu, Ph.D

Role: CONTACT

[email protected]
886-2-23123456 ext. 2117

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kwan-Dun Wu, Ph.D

Role: primary

[email protected]
886-2-23123456 ext. 2117

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

930404

Identifier Type: -

Identifier Source: org_study_id